Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage.
Alzheimers Dement
April 2024
Washington University School of Medicine in Saint Louis, St. Louis, Missouri, USA.
Introduction: Amyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin-1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre-/postcodon 200) influences these pathologic features and dementia at different stages.
Methods: Individuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments.
Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [F]Florzolotau PET imaging and subtype/stage inference algorithm.
EBioMedicine
November 2023
Department of Nuclear Medicine, Inselspital, University of Bern, Bern, Switzerland; Department of Informatics, Technical University of Munich, Munich, Germany.
Background: Progressive supranuclear palsy (PSP) is a primary 4-repeat tauopathy with diverse clinical phenotypes. Previous post-mortem studies examined tau deposition sequences in PSP, but in vivo scrutiny is lacking.
Methods: We conducted [F]Florzolotau tau positron emission tomography (PET) scans on 148 patients who were clinically diagnosed with PSP and 20 healthy controls.
Introduction: The early detection of cognitive impairment is one of the most important challenges in Alzheimer's disease (AD) research. The use of brief, short-term repeated test sessions via mobile app has demonstrated similar or better reliability and validity compared to standard in-clinic assessments in adult samples. The present study examined adherence, acceptability, and reliability for a remote, app-based cognitive screening protocol in healthy older adults.
View Article and Find Full Text PDFSNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer-Regulatory Process, Part I: How and When Radiopharmaceuticals Can Be Used.
J Nucl Med Technol
March 2022
Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
For CE credit, you can access the test for this article, as well as additional CE tests, online at https://www.snmmilearningcenter.org Complete the test online no later than March 2025.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!